The Morning Briefing: Pharmaceutical politics

Summary:"The Morning Briefing" is SmartPlanet's daily roundup of must-reads from the web. This morning we're reading about pharmaceutical politics.

"The Morning Briefing" is SmartPlanet's daily roundup of must-reads from the web. This morning we're reading about pharmaceutical politics.

1.) Endo, Watson settle patent suits on pain reliever. Endo Health Solutions Inc settled two patent lawsuits with Watson Pharmaceuticals Inc., allowing Watson to launch a generic version of Endo's pain-relieving patch, pending approval from U.S. health regulators.

2.) Provinces want compensation for EU drug patents demands. The provincial premiers have undertaken a letter-writing campaign to demand compensation from the federal government for any increase in drug costs that might come of a free trade agreement with Europe.

3.) Lilly chief skeptical of buyouts--and not just megadeals. Does any pharma CEO really need to take the no-megadeals pledge these days?

4.) Pfizer plans animal health IPO. Pfizer Inc plans to separate its animal health unit into a stand-alone company, a move Wall Street expected as the largest U.S. drugmaker focuses more intently on its core pharmaceuticals business.

5.) Medicis sues two competitors over patent infringement. Medicis Pharmaceutical Corp. has filed a patent infringement lawsuit against New Jersey-based Zydus Pharmaceuticals USA Inc. and India-based Cadila Healthcare Ltd.

Image credit: e-MagineArt.com

Related:

This post was originally published on Smartplanet.com

Topics: Innovation

About

Charlie Osborne, a medical anthropologist who studied at the University of Kent, UK, is a journalist, freelance photographer and former teacher. She has spent years travelling and working across Europe and the Middle East as a teacher, and has been involved in the running of businesses ranging from media and events to B2B sales. Charli... Full Bio

zdnet_core.socialButton.googleLabel Contact Disclosure

Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.

Related Stories

The best of ZDNet, delivered

You have been successfully signed up. To sign up for more newsletters or to manage your account, visit the Newsletter Subscription Center.
Subscription failed.